Eddie Williams has been promoted to senior vice president of biopharmaceuticals at Novo Nordisk.


Novo Nordisk, Eddie Williams, senior vice president of biopharmaceuticals, Jesper Hoiland, Novo Nordisk Inc., diabetes care, pharmaceutical industry, biological therapies




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Novo Nordisk promotes pharma veteran

January 30th, 2014

PRINCETON, N.J. – Eddie Williams has been promoted to senior vice president of biopharmaceuticals at Novo Nordisk.

The diabetes care company said Thursday that Williams, currently corporate vice president of biopharmaceuticals, takes over the new post effective Feb. 1.

Novo Nordisk noted that Williams, who joined the company in 2006, has three decades of experience in the pharmaceutical industry. As corporate vice president of biopharmaceuticals, he leads the sales and marketing, business development and new product commercialization functions for the company's growing U.S. biopharmaceuticals business, which develops medicines for people with hemophilia, as well as various types of hormone deficiencies.

"Our biopharmaceutical business will be increasingly important to our growth in the U.S. as we apply the protein expertise developed through our diabetes franchise to helping people with hemophilia and growth disorders manage their conditions more effectively," stated Jesper Hoiland, president of Novo Nordisk Inc., the company's U.S. affiliate. "That business has flourished under Eddie's experienced leadership. His promotion to senior vice president demonstrates the company's focus on, and commitment to, our pipeline of life-changing biological therapies."

Advertisement